IL3 and acute myeloid leukemia: The 7G3 monoclonal antibody was humanised and affinity-matured and it was engineered at the level of the Fc-domain to optimise potential cytotoxicity against AML cells: the resultant antibody, CSL362, retained the ability to neutralise IL-3 and exhibited enhnaced affinity for the FcgammaRIIIa (CD16) on NK cells [62].